Price
No data yet.
Social Signal Score
Revenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Joshua T. Brumm
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 44
- Beta
- 1.23
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 17.67
Financials
Revenue
$0.00-100.0%Net Income
$-22.69MEBITDA
$-24.77MFree Cash Flow
$-19.48MEPS (diluted)
$-0.74Shares Outstanding (diluted)
30.53M+13146.5%Operating Expenses
$28.13MCash & Debt
$171.59MRevenue by Segment (annual)
$10.84MDividend per Share
$24.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $10.84M | $-153.94M | $-14.78 |
| 2024 | $0.00 | $-48.52M | $-63.22 |
| 2023 | $10.0K | $-36.90M | $-58.25 |
| 2022 | $75.0K | $-46.69M | $-88.88 |
| 2021 | $1.16M | $-63.43M | $-123.27 |
| 2020 | $10.16M | $-51.03M | $-111.60 |
| 2019 | $0.00 | $-54.12M | $-133.84 |
| 2018 | $0.00 | $-48.27M | $-117.61 |
| 2017 | $0.00 | $-33.28M | $-113.22 |
| 2016 | $18.5K | $-31.81M | $-149.65 |
| 2015 | $20.07M | $-12.77M | $-67.17 |
| 2014 | $15.03M | $-11.12M | $-60.27 |
| 2013 | $3.99M | $-10.61M | $-199.32 |
| 2012 | $15.26M | $3.66M | $305.64 |
Valuation
CBIOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100Social Signal Score
Mentions (1)
- Newsglobenewswire.com·7h ago·Neutral
…harma to Present at September Investor Conferences WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in September: 2026 Cantor Global Healthcare Conference, fireside chat on Thursday, September 10, 2026 at 1:35 p.m.
View source ↗
Earnings
Thu, Nov 5(in 2 months)
Consensus estimate $-0.67 per share
Typical surprise -0.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$-0.74 vs $-0.74miss
- Wed, Apr 29$-0.70 vs $-0.85beat
- Thu, Feb 26$-4.01 vs $-2.22miss
- Thu, Nov 6$-1.27 vs $-1.01miss
- Wed, Aug 6$-4.93 vs $-2.69miss
- Wed, May 14$-0.04 vs $-5.00beat
Estimates and results for CBIO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CBIO officers and directors.
- Bought
- $30.8m
- Sold
- $1.7m
9 trades
16 trades
- Fairmount Funds Management Llcbought
- Fairmount Funds Management Llcbought
- Lynch Ryansold
- Pinkas Jansold
- Scalzo Richard Williamsold
- Bispham Barbara Harlinsold
- Im Ellie Eunkyungsold
- Mcneill Jonathansold
75 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.